Chronic inflammatory demyelinating polyneuropathy
Adjust the patient characteristics. Results update as you go. Full criteria table
Draft. Coverage criteria for CIDP therapies in Alberta. Efgartigimod SC (Vyvgart SC) received a conditional CDA-AMC reimbursement recommendation in January 2026 but is not yet listed in Alberta; its entry evaluates the anticipated criteria without declaring it covered. Immune globulin criteria follow the Prairie provinces immune globulin guideline. All entries are draft pending verification against the payer documents.